A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.

A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children. - A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000374

Enrollment

Registered

2006-04-01

Start date

1998-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy in children

Interventions

prednisolone+warfarin+dipyridamole for 2 years

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Newly biopsy proven IgA nephropathy with diffuse mesangial proliferation 2.Aged 2 to 18 years 3.Written informed consent from the patients' parents or legal guardians

Exclusion criteria

Exclusion criteria: 1.Nephrotic syndrome 2.Systemic diseases defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus, etc) 3.Medical history of allergy or hypersensitivity reactions to prednisolone, warfarin or dipyridamole 3.Chronic renal dysfunction 4.Active infectious disease 5.Severe liver disfunction 6.History of corticosteroid and immunosupression administration 7.Pregnancy 8.Judged inappropriate for this study by the physicians

Design outcomes

Primary

Measure	Time frame
Disappearance rate of proteinuria	—

Countries

Japan

Contacts

Public ContactKoichi Nakanishi

The Japanese Pediatric IgA Nephropathy of Treatment Study Group Department of Pediatrics, Wakayama Medical University

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026